FDA label 36fd883a-93f8-1fa2-e054-00144ff8d46c

BOXED WARNING WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA­-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Risperidone is not approved for the treatment of patients with dementia-related psychosis. (See Warnings and Precautions 5.1 ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for use in patients with dementia-related psychosis. 5.1

<table ID="id0d01450-0381-4b7f-8d94-82b1c675244a" border="0" cellpadding="3" cellspacing="1" width="444"> <tbody> <tr> <td> </td> </tr> <tr> <td> <paragraph> WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for use in patients with dementia-related psychosis. 5.1 <content styleCode="bold"/> </paragraph> </td> </tr> </tbody> </table>

WARNINGS AND PRECAUTIONS 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis [see Boxed Warning ]. 5.2 Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients with Dementia-Related Psychosis Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients (mean age 85 years; range 73-97) in trials of risperidone in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with risperidone compared to patients treated with placebo. Risperidone is not approved for the treatment of patients with dementia-related psychosis. [See also Boxed Warnings and Warnings and Precautions (5.1) ] 5.3 Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. 5.4 Tardive Dyskinesia A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, risperidone should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that: (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient treated with risperidone, drug discontinuation should be considered. However, some patients may require treatment with risperidone despite the presence of the syndrome. 5.5 Hyperglycemia and Diabetes Mellitus Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including risperidone. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. 5.6 Hyperprolactinemia As with other drugs that antagonize dopamine D 2 receptors, risperidone elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. An increase in pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats [see Non-Clinical Toxicology (13.1) ]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. 5.7 Orthostatic Hypotension Risperidone may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.2% (6/2607) of risperidone-treated patients in Phase 2 and 3 studies in adults with schizophrenia. The risk of orthostatic hypotension and syncope may be minimized by limiting the initial dose to 2 mg total (either once daily or 1 mg twice daily) in normal adults and 0.5 mg twice daily in the elderly and patients with renal or hepatic impairment [see Dosage and Administration(2.1, 2.4) ]. Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. A dose reduction should be considered if hypotension occurs. Risperidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension, e.g., dehydration and hypovolemia. Clinically significant hypotension has been observed with concomitant use of risperidone and antihypertensive medication. 5.8 Potential for Cognitive and Motor Impairment Somnolence was a commonly reported adverse event associated with risperidone treatment, especially when ascertained by direct questioning of patients. This adverse event is dose-related, and in a study utilizing a checklist to detect adverse events, 41% of the high-dose patients (risperidone 16 mg/day) reported somnolence compared to 16% of placebo patients. Direct questioning is more sensitive for detecting adverse events than spontaneous reporting, by which 8% of risperidone 16 mg/day patients and 1% of placebo patients reported somnolence as an adverse event. Since risperidone has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that risperidone therapy does not affect them adversely. 5.9 Seizures During premarketing testing in adult patients with schizophrenia, seizures occurred in 0.3% (9/2607) of risperidone-treated patients, two in association with hyponatremia. Risperidone should be used cautiously in patients with a history of seizures. 5.10 Dysphagia Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer’s dementia. Risperidone and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [See also Boxed Warning and Warnings and Precautions (5.1) ] 5.11 Priapism Rare cases of priapism have been reported. While the relationship of the events to risperidone use has not been established, other drugs with alpha-adrenergic blocking effects have been reported to induce priapism, and it is possible that risperidone may share this capacity. Severe priapism may require surgical intervention. 5.12 Thrombotic Thrombocytopenic Purpura (TTP) A single case of TTP was reported in a 28 year-old female patient receiving oral risperidone in a large, open premarketing experience (approximately 1300 patients). She experienced jaundice, fever, and bruising, but eventually recovered after receiving plasmapheresis. The relationship to risperidone therapy is unknown. 5.13 Body Temperature Regulation Disruption of body temperature regulation has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have been reported in association with oral risperidone use. Caution is advised when prescribing for patients who will be exposed to temperature extremes. 5.14 Antiemetic Effect Risperidone has an antiemetic effect in animals; this effect may also occur in humans, and may mask signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye’s syndrome, and brain tumor. 5.15 Suicide The possibility of a suicide attempt is inherent in patients with schizophrenia and bipolar mania, including children and adolescent patients, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for risperidone should be written for the smallest quantity of tablets, consistent with good patient management, in order to reduce the risk of overdose. 5.16 Use in Patients with Concomitant Illness Clinical experience with risperidone in patients with certain concomitant systemic illnesses is limited. Patients with Parkinson’s Disease or Dementia with Lewy Bodies who receive antipsychotics, including risperidone, are reported to have an increased sensitivity to antipsychotic medications. Manifestations of this increased sensitivity have been reported to include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome. Caution is advisable in using risperidone in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Risperidone has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from clinical studies during the product's premarket testing. Increased plasma concentrations of risperidone and 9-hydroxyrisperidone occur in patients with severe renal impairment (creatinine clearance greater then 30 mL/min/1.73 m 2 ), and an increase in the free fraction of risperidone is seen in patients with severe hepatic impairment. A lower starting dose should be used in such patients [see Dosage and Administration (2.4) ]. 5.17 Monitoring: Laboratory Tests No specific laboratory tests are recommended. Risperidone is not approved for use in patients with dementia-related psychosis (5.2) Neuroleptic Malignant Syndrome (5.3) Tardive dyskinesia (5.4) Hyperglycemia and diabetes mellitus (5.5) Hyperprolactinemia (5.6) Orthostatic hypotension (5.7) Potential for cognitive and motor impairment (5.8) Seizures (5.9) Dysphagia (5.10) Priapism (5.11) Thrombotic Thrombocytopenic Purpura (TTP) (5.12) Disruption of body temperature regulation (5.13) Antiemetic Effect (5.14) Suicide (5.15) Increased sensitivity in patients with Parkinson’s disease or those with dementia with Lewy bodies (5.16) Diseases or conditions that could affect metabolism or hemodynamic responses (5.16)

ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions (5.1) ] Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.2) ] Neuroleptic malignant syndrome [see Warnings and Precautions (5.3) ] Tardive dyskinesia [see Warnings and Precautions (5.4) ] Hyperglycemia and diabetes mellitus [see Warnings and Precautions (5.5) ] Hyperprolactinemia [see Warnings and Precautions (5.6) ] Orthostatic hypotension [see Warnings and Precautions (5.7) ] Potential for cognitive and motor impairment [see Warnings and Precautions (5.8) ] Seizures [see Warnings and Precautions (5.9) ] Dysphagia [see Warnings and Precautions (5.10) ] Priapism [see Warnings and Precautions (5.11) ] Thrombotic Thrombocytopenic Purpura (TTP) [see Warnings and Precautions (5.12) ] Disruption of body temperature regulation [see Warnings and Precautions (5.13) ] Antiemetic effect [see Warnings and Precautions (5.14) ] Suicide [see Warnings and Precautions (5.15) ] Increased sensitivity in patients with Parkinson’s disease or those with dementia with Lewy bodies [see Warnings and Precautions (5.16) ] Diseases or conditions that could affect metabolism or hemodynamic responses [see Warnings and Precautions (5.16) ] The most common adverse reactions in clinical trials (less then 10%) were somnolence, appetite increased, fatigue, rhinitis, upper respiratory tract infection, vomiting, coughing, urinary incontinence, saliva increased, constipation, fever, Parkinsonism, dystonia, abdominal pain, anxiety, nausea, dizziness, dry mouth, tremor, rash, akathisia, and dyspepsia. The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in less then 1% of adults and/or less then 2% of pediatrics) were somnolence, nausea, abdominal pain, dizziness, vomiting, agitation, and akathisia [see Adverse Reactions (6.5) The data described in this section are derived from a clinical trial database consisting of 9712 adult and pediatric patients exposed to one or more doses of risperidone for the treatment of schizophrenia, bipolar mania, or autistic disorder and other psychiatric disorders in pediatrics and elderly patients with dementia. Of these 9712 patients, 2626 were patients who received risperidone while participating in double-blind, placebo-controlled trials. The conditions and duration of treatment with risperidone varied greatly and included (in overlapping categories) double-blind, fixed- and flexible-dose, placebo- or active-controlled studies and open-label phases of studies, inpatients and outpatients, and short-term (up to 12 weeks) and longer-term (up to 3 years) exposures. Safety was assessed by collecting adverse events and performing physical examinations, vital signs, body weights, laboratory analyses, and ECGs. Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using WHOART terminology. Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of risperidone (adverse drug reactions) based on the comprehensive assessment of the available adverse event information. A causal association for risperidone often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The majority of all adverse reactions were mild to moderate in severity. 6.1 Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizophrenia Adult Patients with Schizophrenia Table 1 lists the adverse reactions reported in 1% or more of risperidone-treated adult patients with schizophrenia in three 4- to 8-week, double-blind, placebo-controlled trials. Table 1. Adverse Reactions in less then 1% of Risperidone-Treated Adult Patients with Schizophrenia in Double-Blind, Placebo-Controlled Trials Percentage of Patients Reporting Event Risperidone Body System Adverse Reaction 2-8 mg per day (N=366) >8-16 mg per day (N=198) Placebo (N=225) Body as a whole - general disorders Back pain 3 2 greater then 1 Fatigue 3 1 0 Chest pain 3 1 2 Fever 2 1 1 Asthenia 1 1 greater then 1 Syncope Less then 1 1 greater then 1 Edema less then 1 1 0 Cardiovascular disorders, general Hypotension postural 2 greater then 1 0 Hypotension greater then 1 1 0 Central and peripheral nervous system disorders Parkinsonism* 12 17 6 Dizziness 10 4 2 Dystonia* 5 5 2 Akathisia* 5 5 2 Dyskinesia 1 1 greater then 1 Gastrointestinal system disorders Dyspepsia 10 7 6 Nausea 9 4 4 Constipation 8 9 7 Abdominal pain 4 3 0 Mouth dry 4 less then 1 greater then 1 Saliva increased 3 1 greater then 1 Diarrhea 2 less then 1 1 Hearing and vestibular disorders Earache 1 1 0 Heart rate and rhythm disorders Tachycardia 2 5 0 Arrhythmia 0 1 0 Metabolic and nutritional disorders Weight increase 1 less then 1 0 Creatine phosphokinase increased greater then 1 2 greater then 1 Musculoskeletal system disorders Arthralgia 2 3 greater then 1 Myalgia 1 0 0 Platelet, bleeding and clotting disorders Epistaxis greater then 1 2 0 Psychiatric disorders Anxiety 16 12 11 Somnolence 14 5 4 Anorexia 2 0 greater then 1 Red blood cell disorders Anemia greater then 1 1 0 Reproductive disorders, male Ejaculation failure greater then 1 1 0 Respiratory system disorders Rhinitis 7 11 6 Coughing 3 3 3 Upper respiratory tract infection 2 3 greater then 1 Dyspnea 2 2 0 Skin and appendages disorders Rash 2 4 2 Seborrhea greater then 1 2 0 Urinary system disorders Urinary tract infection greater then 1 3 0 Vision disorders Vision abnormal 3 1 greater then 1 * Parkinsonism includes extrapyramidal disorder, hypokinesia, and bradycardia. Dystonia includes dystonia, hypertonia, oculogyric crisis, muscle contractions involuntary, tetany, laryngismus, tongue paralysis, and torticollis. Akathisia includes hyperkinesia and akathisia. Pediatric Patients with Schizophrenia 6.4 Other Adverse Reactions Observed During the Premarketing Evaluation of Risperidone The following adverse reactions occurred in greater then 1% of the adult patients and in greater then 5% of the pediatric patients treated with risperidone in the above double-blind, placebo-controlled clinical trial data sets. In addition, the following also includes adverse reactions reported in risperidone-treated patients who participated in other studies, including double-blind, active-controlled and open-label studies in schizophrenia and bipolar mania studies in pediatric patients with psychiatric disorders other than schizophrenia, bipolar mania, or autistic disorder and studies in elderly patients with dementia. Body as a Whole, General Disorders: edema peripheral, pain, influenza-like symptoms, leg pain, malaise, allergy, crying abnormal, allergic reaction, rigors, allergy aggravated, anaphylactoid reaction, hypothermia Central Nervous System Disorders: gait abnormal, speech disorder, coma, ataxia, dysphonia, stupor, cramps legs, vertigo, hypoesthesia, tardive dyskinesia, neuroleptic malignant syndrome Endocrine Disorders: hyperprolactinemia, gynecomastia Gastrointestinal System Disorders: dysphagia, flatulence Heart Rate and Rhythm Disorders: AV block, bundle branch block Liver and Biliary Disorders: SGPT increased, hepatic enzymes increased Metabolic and Nutritional Disorders: thirst, hyperglycemia, xerophthalmia, generalized edema, diabetes mellitus aggravated, diabetic coma Musculoskeletal Disorders: muscle weakness, rhabdomyolysis Platelet, Bleeding, and Clotting Disorders: purpura Psychiatric Disorders: insomnia, agitation, emotional lability, apathy, nervousness, concentration impaired, impotence, decreased libido Reproductive Disorders, Female: amenorrhea, menstrual disorder, leukorrhea Reproductive Disorders, Male: ejaculation disorder, abnormal sexual function, priapism Resistance Mechanism Disorders: otitis media, viral infection Respiratory Disorders: respiratory disorder Skin and Appendages Disorders: skin ulceration, skin discoloration, rash erythematous, skinexfoliation, rash maculopapular, erythema multiforme Urinary Disorders: micturition frequency Vascular Disorders: cerebrovascular disorder Vision Disorders: conjunctivitis White Cell Disorders: leucopenia, granulocytopenia Dystonia Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. Other Adverse Reactions Adverse event data elicited by a checklist for side effects from a large study comparing 5 fixed doses of risperidone (1, 4, 8, 12, and 16 mg/day) were explored for dose-relatedness of adverse events. A Cochran-Armitage Test for trend in these data revealed a positive trend (pless then 0.05) for the following adverse reactions: somnolence, vision abnormal, dizziness, palpitations, weight increase, erectile dysfunction, ejaculation disorder, sexual function abnormal, fatigue, and skin discoloration. 6.7 Changes in Body Weight The proportions of risperidone and placebo-treated adult patients with schizophrenia meeting a weight gain criterion of less then 7% of body weight were compared in a pool of 6- to 8-week, placebo-controlled trials, revealing a statistically significantly greater incidence of weight gain for risperidone (18%) compared to placebo (9%). In a pool of placebo-controlled 3-week studies in adult patients with acute mania, the incidence of weight increase of less then 7% at endpoint was comparable in the risperidone (2.5%) and placebo (2.4%) groups, and was slightly higher in the active-control group (3.5%). Changes in body weight were also evaluated in pediatric patients [see Use in Specific Populations (8.4) ] 6.8 Changes in ECG Between-group comparisons for pooled placebo-controlled trials in adults revealed no statistically significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including QT, QTc, and PR intervals, and heart rate. When all risperidone doses were pooled from randomized controlled trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for placebo patients. In short-term schizophrenia trials, higher doses of risperidone (8-16 mg/day) were associated with a higher mean increase in heart rate compared to placebo (4-6 beats per minute). In pooled placebo-controlled acute mania trials in adults, there were small decreases in mean heart rate, similar among all treatment groups. Due to Janssen Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia, bipolar mania or autistic disorder. Information regarding changes in ECG during the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, and the treatment of pediatric patients with irritability associated with autistic disorder, 5 to 16 years of age, is approved for Janssen Pharmaceuticals Corporation’s risperidone drug products 6.9 Postmarketing Experience The following adverse reactions have been identified during postapproval use of risperidone; because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency: agranulocytosis, alopecia, anaphylactic reaction, angioedema, atrial fibrillation, diabetic ketoacidosis in patients with impaired glucose metabolism, inappropriate antidiuretic hormone secretion, intestinal obstruction, jaundice, mania, pancreatitis, QT prolongation, sleep apnea, thrombocytopenia, and water intoxication. Other adverse events reported since market introduction, which were temporally related to risperidone but not necessarily causally related, include the following: pituitary adenoma, pulmonary embolism, precocious puberty, cardiopulmonary arrest, and sudden death. The most common adverse reactions in clinical trials less then 10% were somnolence, appetite increased, fatigue, rhinitis, upper respiratory tractinfection, vomiting, coughing, urinary incontinence, saliva increased,constipation, fever, Parkinsonism, dystonia, abdominal pain, anxiety, nausea, dizziness, dry mouth, tremor, rash, akathisia, and dyspepsia. 6 The most common adverse reactions that were associated with discontinuation from clinical trials were somnolence, nausea, abdominal pain, dizziness, vomiting, agitation, and akathisia. 6 To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy's Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

<table border="0" cellpadding="0" cellspacing="0" ID="i72a5fbfd-c1fc-4854-8e14-d514c7567534"> <caption/> <tbody> <tr> <td> <paragraph/> </td> </tr> </tbody> <tbody> <tr> <td> <content styleCode="bold">Percentage of Patients Reporting Event </content> <content styleCode="bold">Risperidone</content> </td> </tr> </tbody> <tbody> <tr> <td> <content styleCode="bold">Body System </content> <paragraph/> <paragraph/> Adverse Reaction <content styleCode="bold"/> </td> <td> <content styleCode="bold">2-8 mg per day </content> <paragraph/> <paragraph/> <content styleCode="bold">(N=366)</content> </td> <td> <content styleCode="bold">&gt;8-16 mg per</content> <content styleCode="bold"> day </content> <paragraph/> <paragraph/> <content styleCode="bold">(N=198)</content> </td> <td> <content styleCode="bold">Placebo </content> <paragraph/> <paragraph/> <content styleCode="bold">(N=225)</content> <content styleCode="bold"/> </td> </tr> <tr> <td> <content styleCode="bold">Body as a whole - general disorders </content> </td> <td> <content styleCode="bold"/> </td> <td> <content styleCode="bold"/> </td> <td> <content styleCode="bold"/> </td> </tr> <tr> <td>Back pain</td> <td>3</td> <td>2</td> <td>greater then 1</td> </tr> <tr> <td>Fatigue</td> <td>3</td> <td>1</td> <td>0</td> </tr> <tr> <td>Chest pain</td> <td>3</td> <td>1</td> <td>2</td> </tr> <tr> <td>Fever</td> <td>2</td> <td>1</td> <td>1</td> </tr> <tr> <td>Asthenia</td> <td>1</td> <td>1</td> <td>greater then 1</td> </tr> <tr> <td>Syncope</td> <td>Less then 1</td> <td>1</td> <td>greater then 1</td> </tr> <tr> <td>Edema</td> <td>less then 1</td> <td>1</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Cardiovascular disorders, general </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Hypotension postural</td> <td>2</td> <td>greater then 1</td> <td>0</td> </tr> <tr> <td>Hypotension</td> <td>greater then 1</td> <td>1</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Central and peripheral nervous system disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Parkinsonism*</td> <td>12</td> <td>17</td> <td>6</td> </tr> <tr> <td>Dizziness</td> <td>10</td> <td>4</td> <td>2</td> </tr> <tr> <td>Dystonia*</td> <td>5</td> <td>5</td> <td>2</td> </tr> <tr> <td>Akathisia*</td> <td>5</td> <td>5</td> <td>2</td> </tr> <tr> <td>Dyskinesia</td> <td>1</td> <td>1</td> <td>greater then 1</td> </tr> <tr> <td> <content styleCode="bold">Gastrointestinal system disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Dyspepsia</td> <td>10</td> <td>7</td> <td>6</td> </tr> <tr> <td>Nausea</td> <td>9</td> <td>4</td> <td>4</td> </tr> <tr> <td>Constipation</td> <td>8</td> <td>9</td> <td>7</td> </tr> <tr> <td>Abdominal pain</td> <td>4</td> <td>3</td> <td>0</td> </tr> <tr> <td>Mouth dry</td> <td>4</td> <td>less then 1</td> <td>greater then 1</td> </tr> <tr> <td>Saliva increased</td> <td>3</td> <td>1</td> <td>greater then 1</td> </tr> <tr> <td>Diarrhea</td> <td>2</td> <td>less then 1</td> <td>1</td> </tr> <tr> <td> <content styleCode="bold">Hearing and vestibular disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Earache</td> <td>1</td> <td>1</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Heart rate and rhythm disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Tachycardia</td> <td>2</td> <td>5</td> <td>0</td> </tr> <tr> <td>Arrhythmia</td> <td>0</td> <td>1</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Metabolic and nutritional disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Weight increase</td> <td>1</td> <td>less then 1</td> <td>0</td> </tr> <tr> <td>Creatine phosphokinase increased</td> <td>greater then 1</td> <td>2</td> <td>greater then 1</td> </tr> <tr> <td> <content styleCode="bold">Musculoskeletal system disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Arthralgia</td> <td>2</td> <td>3</td> <td>greater then 1</td> </tr> <tr> <td>Myalgia</td> <td>1</td> <td>0</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Platelet, bleeding and clotting disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Epistaxis</td> <td>greater then 1</td> <td>2</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Psychiatric disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Anxiety</td> <td>16</td> <td>12</td> <td>11</td> </tr> <tr> <td>Somnolence</td> <td>14</td> <td>5</td> <td>4</td> </tr> <tr> <td>Anorexia</td> <td>2</td> <td>0</td> <td>greater then 1</td> </tr> <tr> <td> <content styleCode="bold">Red blood cell disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Anemia</td> <td>greater then 1</td> <td>1</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Reproductive disorders, male </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Ejaculation failure</td> <td>greater then 1</td> <td>1</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Respiratory system disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Rhinitis</td> <td>7</td> <td>11</td> <td>6</td> </tr> <tr> <td>Coughing</td> <td>3</td> <td>3</td> <td>3</td> </tr> <tr> <td>Upper respiratory tract infection</td> <td>2</td> <td>3</td> <td>greater then 1</td> </tr> <tr> <td>Dyspnea</td> <td>2</td> <td>2</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Skin and appendages disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Rash</td> <td>2</td> <td>4</td> <td>2</td> </tr> <tr> <td>Seborrhea</td> <td>greater then 1</td> <td>2</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Urinary system disorders </content> </td> <td/> <td/> <td/> </tr> <tr> <td>Urinary tract infection </td> <td>greater then 1</td> <td>3</td> <td>0</td> </tr> <tr> <td> <content styleCode="bold">Vision disorders</content> </td> <td/> <td/> <td/> </tr> <tr> <td>Vision abnormal</td> <td>3</td> <td>1</td> <td>greater then 1</td> </tr> </tbody> </table>

<table border="0" cellpadding="3" cellspacing="1" width="467" ID="i52d4a8a1-8fde-4ad8-8dbf-83b9920fb708"> <tbody> <tr> <td> <paragraph>The most common adverse reactions in clinical trials less then 10% were somnolence, appetite increased, fatigue, rhinitis, upper respiratory tractinfection, vomiting, coughing, urinary incontinence, saliva increased,constipation, fever, Parkinsonism, dystonia, abdominal pain, anxiety, nausea, dizziness, dry mouth, tremor, rash, akathisia, and dyspepsia. 6 </paragraph> <paragraph>The most common adverse reactions that were associated with discontinuation from clinical trials were somnolence, nausea, abdominal pain, dizziness, vomiting, agitation, and akathisia. 6</paragraph> <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy&apos;s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</paragraph> </td> </tr> <tr> <td> </td> </tr> </tbody> </table>